Effects of maternally-derived antibodies on serologic responses to vaccination in kittens

DiGangi, Brian A.; Levy, Julie; Griffin, Brenda; Reese, Michael J.; Dingman, Patricia A.; Tucker, Sylvia J; Dubovi, Edward J.

doi:10.1177/1098612x11432239

Cited by 39 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dawson et al observed a high number of kittens without antibody response at the age of 15 weeks after two or three vaccinations (25 and 39% respectively) [16]. Similar results were obtained in other studies [17,18]. Reports of severe disease in vaccinated animals indicate the clinical significance of non-responding cats and dogs [4,19,20].…”

Section: Introductionsupporting

confidence: 59%

“…Dawson et al showed that only 75% of kittens seroconverted after multiple vaccinations until 12 weeks of age [16]. Similar results were reported in recent studies [17,18]. The lack of successful immunisation following the recommended vaccination scheme explains the occurrence of clinical disease in the post-weaning period both in vaccinated as well as non-vaccinated animals [4].…”

Section: Discussionmentioning

confidence: 72%

See 1 more Smart Citation

Vaccination against Feline Panleukopenia: implications from a field study in kittens

et al. 2012

View full text Add to dashboard Cite

BackgroundFeline Panleukopenia (FPL) is a serious disease of cats that can be prevented by vaccination. Kittens are routinely vaccinated repeatedly during their first months of life. By this time maternally derived antibodies (MDA) can interfere with vaccination and inhibit the development of active immunity. The efficacy of primary vaccination under field conditions was questioned by frequent reports to the Paul-Ehrlich-Institut on outbreaks of FPL in vaccinated breeding catteries. We therefore initiated a field study to investigate the development of immunity in kittens during primary vaccination against FPL.64 kittens from 16 litters were vaccinated against FPL at the age of 8, 12 and 16 weeks using three commercial polyvalent vaccines. Blood samples were taken before each vaccination and at the age of 20 weeks. Sera were tested for antibodies against Feline Panleukopenia Virus (FPV) by hemagglutination inhibition test and serum neutralisation assay in two independent diagnostic laboratories.ResultsThere was a good correlation between the results obtained in different laboratories and with different methods. Despite triple vaccination 36.7% of the kittens did not seroconvert. Even very low titres of MDA apparently inhibited the development of active immunity. The majority of kittens displayed significant titres of MDA at 8 and 12 weeks of age; in some animals MDA were still detected at 20 weeks of age. Interestingly, the vaccines tested differed significantly in their ability to overcome low levels of maternal immunity.ConclusionsIn the given situation it is recommended to quantify antibodies against FPV in the serum of the queen or kittens before primary vaccination of kittens. The beginning of primary vaccination should be delayed until MDA titres have declined. Unprotected kittens that have been identified serologically should be revaccinated.

show abstract

Section: Introductionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 72%

Vaccination against Feline Panleukopenia: implications from a field study in kittens

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A crucial feature of an idealised vaccination protocol for cats in any country would include a finish to the kitten series no earlier than 16 weeks of age. This is because evidence has accumulated in recent years indicating that a sizeable minority of kittens have significant amounts of interfering maternal antibodies against some of the vaccine components, even at up to 20 weeks of age (Digangi et al 2012, Jakel et al 2012a [EB1]. A 16 weeks or later finish is consistent with this scientific evidence and with the current WSAVA vaccination guidelines, as well as with guidelines from other organisations.…”

Section: Feline Vaccination: Aspirational Protocolsmentioning

confidence: 70%

Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group

Day

Crawford

Marcondes

et al. 2020

J of Small Animal Practice

View full text Add to dashboard Cite

Executive Summary The World Small Animal Veterinary Association Vaccination Guidelines Group has produced global guidelines for small companion animal practitioners on best practice in canine and feline vaccination. Recognising that there are unique aspects of veterinary practice in certain geographical regions of the world, the Vaccination Guidelines Group undertook a regional project in Latin America between 2016 and 2019, culminating in the present document. The Vaccination Guidelines Group gathered scientific and demographic data during visits to Argentina, Brazil and Mexico, by discussion with national key opinion leaders, visiting veterinary practices and review of the scientific literature. A questionnaire survey was completed by 1390 veterinarians in five Latin American countries and the Vaccination Guidelines Group delivered continuing education at seven events attended by over 3500 veterinarians. The Vaccination Guidelines Group recognised numerous challenges in Latin America, for example: (1) lack of national oversight of the veterinary profession, (2) extraordinary growth in private veterinary schools of undetermined quality, (3) socioeconomic constraints on client engagement with preventive health care, (4) high regional prevalence of some key infectious diseases (e.g. feline leukaemia virus infection, canine visceral leishmaniosis), (5) almost complete lack of minimal antigen vaccine products as available in other markets, (6) relative lack of vaccine products with extended duration of immunity as available in other markets, (7) availability of vaccine products withdrawn from other markets (e.g. Giardia vaccine) or unique to Latin America (e.g. some Leishmania vaccines), (8) accessibility of vaccines directly by pet owners or breeders such that vaccination is not delivered under veterinary supervision, (9) limited availability of continuing education in veterinary vaccinology and lack of compulsion for continuing professional development and (10) limited peer‐reviewed published scientific data on small companion animal infectious diseases (with the exception of leishmaniosis) and lack of support for such academic research. In this document, the Vaccination Guidelines Group summarises the findings of this project and assesses in evidence‐based fashion the scientific literature pertaining to companion animal vaccine‐preventable diseases in Latin America. The Vaccination Guidelines Group makes some recommendations on undergraduate and postgraduate education and academic research. Recognising that current product availability in Latin America does not permit veterinarians in these countries to vaccinate according to the global World Small Animal Veterinary Association guidelines, the Vaccination Guidelines Group makes a series of “pragmatic” recommendations as to what might be currently achievable, and a series of “aspirational” recommendations as to what might be desirable for the future. The concept of “vaccine husbandry” is addressed via some simple guidelines for the management of vaccine products i...

show abstract

“…Interference with maternal antibodies is also considered as a major factor in immunisation failure against parvovirosis in other species, such as canine and feline (Carmichael and others 1983, Buonavoglia and others 1992). In these species, successful early vaccination schedules using repeated injections with live attenuated vaccines starting before decline of maternal antibodies have been reported (Buonavoglia and others 1992, Waner and others 1996, Pratelli and others 2000, Dawson and others 2001, Digangi and others 2012). …”

Section: Discussionmentioning

confidence: 99%

Efficacy of a new attenuated duck parvovirosis vaccine in Muscovy ducks

Maurin-Bernaud¹,

Goutebroze²,

Merdy³

et al. 2014

Veterinary Record

View full text Add to dashboard Cite

The efficacy of a new live attenuated parvovirosis vaccine was tested in conventional ducklings against Derzsy's disease by comparing two vaccination regimens. Ducklings were vaccinated with either one injection at 17 days of age or two injections at 1 and 17 days of age. Controls and vaccinated ducklings were challenged with a virulent Derzsy strain at 21 days of age (day 20). Weight was measured on days 20, 34 and 42/43. Surviving birds were necropsied on day 42/43. Protection rates were significantly higher in the groups vaccinated once (90 per cent, P=0.003) and twice (95 per cent, P<0.001) than in the control group (59 per cent). The bodyweight was significantly higher in both vaccinated groups than in the control group on day 34 (P=0.008 and P<0.001, respectively) and day 42/43 (P<0.001 for both groups). The growth was significantly higher in the group vaccinated twice than the group vaccinated once on day 34 (P=0.047) and day 42/43 (P=0.017). Both vaccination regimens provided a quick onset of immunity. The higher weight gain in the group vaccinated twice suggests that an early vaccination at hatchery followed by a second injection at 17 days of age is an optimal and practical schedule to prevent parvovirosis.

show abstract

Effects of maternally-derived antibodies on serologic responses to vaccination in kittens

Cited by 39 publications

References 17 publications

Vaccination against Feline Panleukopenia: implications from a field study in kittens

Vaccination against Feline Panleukopenia: implications from a field study in kittens

Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group

Efficacy of a new attenuated duck parvovirosis vaccine in Muscovy ducks

Contact Info

Product

Resources

About